The COVID-19 pandemic, and the ensuing response by the medical establishment, was an eye-opening experience for tens of millions of Americans.
We watched as the medical establishment put the biopharmaceutical complex’s bottom line above the health and well-being of the American people.
This from thegatewaypundit.com.
Sadly, greed in medicine is not new. In fact, the fight against cancer has taken on the appearance of greed in medicine:
A recent study in the journal Cancer takes a closer look at the impact of cancer drug prices on pharma revenues. Dr. Daniel Meyers at the University of Calgary and colleagues looked at the total revenue generated by ten large pharmaceutical companies from 2010 to 2019, and compared the revenue from cancer and non-cancer drugs.
They found sales from cancer drugs are becoming an increasingly important part of pharmaceutical companies’ revenue. While the annual revenue generated by cancer drugs increased by 70% from 2010 to 2019, the revenue from non-cancer drugs decreased by 18%. In 2010, 14% of total revenue from these ten companies was from cancer drugs; in 2019, cancer drugs made up one quarter of revenue.
Even worse, there is little correlation between the amount of money charged for these drugs and treatments and health outcomes:
If we were getting vastly improved clinical outcomes for these expensive drugs, they might be worth the price. But in the US, the cost of cancer drugs is not correlated with clinical benefit, according to a study in The Lancet Oncology. And once the price of a drug goes above $100,000, it doesn’t matter how good the drug is—when people can’t afford it, they won’t take it.
Unsurprisingly then, big pharma and the medical establishment have absolutely no interest in pursuing low-cost treatments.
Fortunately, medical professionals like Dr. Peter McCullough are committed to delivering healthcare solutions which are safe, effective AND affordable. This is exactly why Dr. McCullough and his team are digging into the potential for ivermectin in combatting cancers.
According to the McCullough Foundation, the early returns of a new study are promising:
The study titled A Review of Ivermectin Use in Cancer Patients: Is it Time to Repurpose the Ivermectin in Cancer Treatment? was just published in the journal Acta Poloniae Pharmaceutica—Drug Research…
Based on the most comprehensive systematic review of ivermectin use in cancer patients to date, ivermectin appears to be safe—even in individuals undergoing active chemotherapy. Its broad range of anticancer mechanisms demonstrated in preclinical models, combined with anecdotal reports of cancer-related improvements, support its candidacy for repurposing as an oncologic therapy.
Well-designed, large-scale clinical trials should be launched as soon as possible to properly assess ivermectin’s potential against cancer.
Indeed, ivermectin in concert with mebendazole has shown even more promise in treating a wide variety of cancers.
Mebendazole, an anti-parasitic like ivermectin, has been prescribed for 100 years to help eradicate parasites—which over 60 million Americans have inside their body today, according to the CDC.
I am grateful to have a medicine as potentially beneficial as ivermectin and mebendazole. I am grateful to Dr. McCullough and The McCullough Foundation for this proven product and the peace in knowing that I’m taking something that is precisely what it states on the labels. – Jennifer W.
My daughter was diagnosed with uterine cancer and lung nodules that turned out to be cancerous. She started taking ivermectin/mebendazole 2 weeks ago. She had a PET scan last month and her lungs were littered with dime and pea sized nodules from the top to the bottom of her lungs. She had a biopsy on the 14th of April and the Physcian had to SEARCH for a nodule big enough to get a sample from, and the ONE that he found was at the bottom of her left lung that he said was only a few centimeters wide…. Thank All of you Doctors for giving us HOPE and HEALING!!! – Helen
